{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:51:49Z","timestamp":1791341509504,"version":"4.3.1"},"reference-count":99,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is one of the most common autosomal recessive diseases with progressive weakness of skeletal and respiratory muscles, leading to significant disability. The disorder is caused by mutations in the survival motor neuron 1 (SMN1) gene and a consequent decrease in the SMN protein leading to lower motor neuron degeneration. Recently, Food and Drug Administration (FDA) and European Medical Agency (EMA) approved the antisense oligonucleotide nusinersen, the first SMA disease-modifying treatment and gene replacement therapy by onasemnogene abeparvovec. Encouraging results from phase II and III clinical trials have raised hope that other therapeutic options will enter soon in clinical practice. However, the availability of effective approaches has raised up ethical, medical and financial issues that are routinely faced by the SMA community. This review covers the available data and the new challenges of SMA therapeutic strategies.<\/jats:p>","DOI":"10.3390\/jcm9072222","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T11:03:23Z","timestamp":1594724603000},"page":"2222","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":141,"title":["New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7994-3391","authenticated-orcid":false,"given":"Sonia","family":"Messina","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"},{"name":"NEuroMuscular Omnicentre (NEMO) Sud Clinical Centre, University Hospital \u201cG. Martino\u201d, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sframeli","sequence":"additional","affiliation":[{"name":"NEuroMuscular Omnicentre (NEMO) Sud Clinical Centre, University Hospital \u201cG. Martino\u201d, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"Mercuri","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: Controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","article-title":"Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy","volume":"162","author":"Farrar","year":"2013","journal-title":"J. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management ofspinal muscular atrophy: Part 2: Pulmonary and acutecare; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and Prenatal diagnosis for spinal muscular atrophy: Clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.ejhg.5201288","article-title":"New insights on the evolution of the SMN1 and SMN2 region: Simulation and meta-analysis for allele and haplotype frequency calculations","volume":"12","author":"Ogino","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_8","first-page":"124","article-title":"Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy\u2013A literature review","volume":"2","author":"Ingrid","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chen, T.H. (2020). New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093297"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Messina, S. (2018). New Directions for SMA Therapy. J. Clin. Med., 7.","DOI":"10.3390\/jcm7090251"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wadman, R.I., van der Pol, W.L., Bosboom, W.M., Asselman, F.L., van den Berg, L.H., Iannaccone, S.T., and Vrancken, A.F. (2019). Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst. Rev., 12.","DOI":"10.1002\/14651858.CD006281.pub5"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wadman, R.I., van der Pol, W.L., Bosboom, W.M., Asselman, F.L., van den Berg, L.H., Iannaccone, S.T., and Vrancken, A.F. (2020). Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst. Rev., 1.","DOI":"10.1002\/14651858.CD006282.pub5"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","article-title":"New treatments in spinal muscular atrophy: An overview of currently available data","volume":"21","author":"Ramdas","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in Treatment of Spinal Muscular Atrophy\u2014New Phenotypes, New Challenges, New Implications for Care","volume":"7","author":"Schorling","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1083\/jcb.201207087","article-title":"Antisense-based therapy for the treatment of spinal muscular atrophy","volume":"199","author":"Rigo","year":"2012","journal-title":"J. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/j.nmd.2019.06.514","article-title":"Interim report on the safety and efficacy of longer-term treatment with nusinersen in later-onset spinal muscular atrophy (SMA): Results from the SHINE study. Presented at the World-Muscle-Society Conference 2019","volume":"29","author":"Kirschner","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen Initiated in Infants During the Presymptomatic Stage of Spinal Muscular Atrophy: Interim Efficacy and Safety Results From the Phase 2 NURTURE Study","volume":"29","author":"Bertini","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.nmd.2017.09.006","article-title":"Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience","volume":"27","author":"Messina","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jnnp-2017-317412","article-title":"Nusinersen for SMA: Expanded access programme","volume":"89","author":"Farrar","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany","volume":"5","author":"Pechmann","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_28","first-page":"1312","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study","volume":"91","author":"Seferian","year":"2018","journal-title":"Neurology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","article-title":"Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function","volume":"28","author":"Pane","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data","volume":"86","author":"Pane","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41467-017-01559-4","article-title":"Binding to SMN2 pre-mRNA-protein Complex Elicits Specificity for Small Molecule Splicing Modifiers","volume":"8","author":"Sivaramakrishnan","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00447","DOI":"10.1002\/prp2.447","article-title":"Risdiplam Distributes and Increases SMN Protein in Both the Central Nervous System and Peripheral Organs","volume":"29","author":"Poirier","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)","volume":"9","author":"Ratni","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","article-title":"Spinal Muscular Atrophy: Going beyond the Motor Neuron","volume":"19","author":"Hamilton","year":"2013","journal-title":"Trends Mol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Yeo, C.J.J., and Darras, B.T. (2020). Overturning the Paradigm of Spinal Muscular Atrophy as just a Motor Neuron Disease. Pediatr. Neurol.","DOI":"10.1016\/j.pediatrneurol.2020.01.003"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bcp.13786","article-title":"A Phase 1 Healthy Male Volunteer Single Escalating Dose Study of the Pharmacokinetics and Pharmacodynamics of Risdiplam (RG7916, RO7034067), a SMN2 Splicing Modifier","volume":"85","author":"Sturm","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_37","first-page":"3","article-title":"FIREFISH Part 1: 1-Year Results on Motor Function in Babies with Type 1 SMA. Presented at the American Academy of Neurology Conference 2019","volume":"92","author":"Baranello","year":"2019","journal-title":"Neurology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/j.nmd.2019.06.515","article-title":"FIREFISH Part 1: 16-Month safety and exploratory outcomes of risdiplam (RG7916) treatment in infants with Type 1 spinal muscular atrophy (SMA). Presented at the World-Muscle-Society Conference 2019","volume":"29","author":"Baranello","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.94.15_supplement.1302","article-title":"FIREFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Infants with Type 1 Spinal Muscular Atrophy (SMA). Presented at the American Academy of Neurology Conference 2020","volume":"94","author":"Servais","year":"2020","journal-title":"Neurology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1212\/WNL.94.15_supplement.1260","article-title":"SUNFISH Part 2: Efficacy and safety of risdiplam (RG7916) in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA) Presented at the American Academy of Neurology Conference 2020","volume":"94","author":"Mercuri","year":"2020","journal-title":"Neurology"},{"key":"ref_41","unstructured":"(2020, May 30). Roche Press Release 07\/04\/2020: Roche Provides Regulatory Update on Risdiplam for the Treatment of Spinal Muscular Atrophy (SMA). Available online: https:\/\/www.roche.com\/media\/releases\/med-cor-2020-04-07.htm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1093\/hmg\/ddr275","article-title":"Temporal requirement for high SMN expression in SMA mice","volume":"20","author":"Le","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1126\/scitranslmed.3000830","article-title":"Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy","volume":"2","author":"Valori","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an AAV vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.88.16_supplement.S13.001","article-title":"AVXS-101 phase 1 gene therapy clinical trial in SMA type 1: Experience with pre-existing anti-AAV9 antibody in the SMA1 population (S13.001)","volume":"88","author":"Sproule","year":"2017","journal-title":"Neurology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort","volume":"6","author":"Kolb","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_50","first-page":"30280","article-title":"Impact of age andmotor function in a phase 1\/2A study of infants with SMA Type 1 receiving single-dose gene replacement therapy","volume":"19","author":"Lowes","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1212\/WNL.94.15_supplement.1828","article-title":"Onasemnogene Abeparvovec-xioi Gene-Replacement Therapy for Spinal Muscular Atrophy Type 1 (SMA1): Phase 3 US Study (STR1VE) Update (1828) Presented at the American Academy of Neurology Conference 2020","volume":"94","author":"Day","year":"2020","journal-title":"Neurology"},{"key":"ref_52","unstructured":"(2020, May 30). Press Release Novartis 2019. Available online: https:\/\/www.novartis.com\/news\/media-releases\/avexis-receives-fda-approval-zolgensma-first-and-only-gene-therapy-pediatric-patients-spinal-muscular-atrophy-sma."},{"key":"ref_53","unstructured":"(2020, May 30). Press Release Novartis 2020. Available online: https:\/\/www.globenewswire.com\/news-release\/2020\/05\/19\/2035354\/0\/en\/AveXis-receives-EC-approval-and-activates-Day-One-access-program-for-Zolgensma-the-only-gene-therapy-for-spinal-muscular-atrophy-SMA.html."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Hwee, D.T., Kennedy, A., Ryans, J., Russell, A.J., Jia, Z., Hinken, A.C., Morgans, D.J., Malik, F.I., and Jasper, J.R. (2014). Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096921"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1113\/JP278235","article-title":"Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction","volume":"597","author":"Cheng","year":"2019","journal-title":"J. Physiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/mus.26017","article-title":"CK-2127107 Amplifies Skeletal Muscle Response to Nerve Activation in Humans","volume":"57","author":"Andrews","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_57","unstructured":"Rudnicki, S.A., Andrews, J.A., and Malik, F.I. (2018, January 16). CY 5021 A phase 2, double-blind, randomized, placebo-controlled, multiple-dose study of reldesemtiv 2 ascending-dose cohorts of patients with Spinal Muscular Atrophy (SMA). Proceedings of the Cure SMA 2018, Dallas, TX, USA."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/hmg\/ddv629","article-title":"Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset","volume":"25","author":"Feng","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/hmg\/ddy382","article-title":"Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy","volume":"28","author":"Long","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1038\/cddis.2013.209","article-title":"Survival motor neuron protein reduction deregulates autophagy in spinal cord motoneurons in vitro","volume":"4","author":"Garcera","year":"2013","journal-title":"Cell. Death Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.expneurol.2016.06.032","article-title":"Autophagy modulators regulate survival motor neuron protein stability in motoneurons","volume":"283","author":"Periyakaruppiah","year":"2016","journal-title":"Exp. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4103\/1673-5374.232473","article-title":"Autophagy inhibition: A new therapeutic target in spinal muscular atrophy","volume":"13","author":"Piras","year":"2018","journal-title":"Neural Regen. Res."},{"key":"ref_63","first-page":"76","article-title":"Neuroprotective effect of non-viral gene therapy treatment based on tetanus toxin C-fragment in a severe mouse model of spinal muscular atrophy","volume":"9","author":"Calvo","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF03033366","article-title":"Survival motor neuron protein regulates apoptosis in an in vitro model of spinal muscular atrophy","volume":"13","author":"Parker","year":"2008","journal-title":"Neurotox. Res."},{"key":"ref_65","first-page":"6986","article-title":"Genetic inhibition of JNK3 ameliorates spinal muscular atrophy","volume":"15","author":"Genabai","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fnmol.2018.00308","article-title":"Pharmacological c-Jun NH2-Terminal Kinase (JNK) Pathway Inhibition Reduces Severity of Spinal Muscular Atrophy Disease in Mice","volume":"11","author":"Schellino","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fncel.2018.00017","article-title":"Increasing Agrin Function Antagonizes Muscle Atrophy and Motor Impairment in Spinal Muscular Atrophy","volume":"12","author":"Boido","year":"2018","journal-title":"Front. Cell Neurosci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/hmg\/ddx124","article-title":"Motor neuronal repletion of the NMJ organizer, Agrin, modulates the severity of the spinal muscular atrophy disease phenotype in model mice","volume":"26","author":"Kim","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_69","first-page":"16","article-title":"Activation of NF-\u03baB pathway in Duchenne muscular dystrophy: Relation to age","volume":"30","author":"Messina","year":"2011","journal-title":"Acta Myol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.1523\/JNEUROSCI.0206-11.2011","article-title":"The canonical nuclear factor-kappa B pathway regulates cell survival in a developmental model of spinal cord Motoneurons","volume":"31","author":"Mincheva","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1007\/s12035-017-0710-4","article-title":"Regulation of Survival Motor Neuron Protein by the Nuclear Factor-Kappa B Pathway in Mouse Spinal Cord Motoneurons","volume":"55","author":"Arumugam","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment in spinal muscular atrophy: Current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Therap. Clin. Risk Manag."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Pera, M.C., Coratti, G., Berti, B., D\u2019Amico, A., Sframeli, M., Albamonte, E., de Sanctis, R., Messina, S., Catteruccia, M., and Brigati, G. (2020). Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230677"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/gim.2017.152","article-title":"Pilot study of population-based newborn screening for spinal muscular atrophy in New York state","volume":"20","author":"Kraszewski","year":"2018","journal-title":"Genet. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JND-190428","article-title":"One year of newborn screening for SMA \u2013 results of a German Pilot Project","volume":"6","author":"Vill","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.nmd.2019.02.003","article-title":"Newborn screening for SMA in Southern Belgium","volume":"29","author":"Boemer","year":"2019","journal-title":"Neuromuscul. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpeds.2017.06.042","article-title":"Presymptomatic diagnosis of Spinal Muscular Atrophy through newborn screening","volume":"190","author":"Chien","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41431-019-0476-4","article-title":"High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR","volume":"28","author":"Czibere","year":"2020","journal-title":"Eur. J. Hum. Gen."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with Spinal Muscular Atrophy through Newborn Screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-200475","article-title":"Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening\u2014Opportunity or Burden?","volume":"7","author":"Vill","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_81","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG) (2020). Newborn Screening for 5q-Linked Spinal Muscular Atrophy: IQWiG Reports. Commission No. S18-02, Institute for Quality and Efficiency in Health Care (IQWiG)."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.gde.2013.03.003","article-title":"How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches","volume":"23","author":"Wirth","year":"2013","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fneur.2019.00898","article-title":"Biomarkers and the development of a personalized medicine approach in Spinal Muscular Atrophy","volume":"10","author":"Kariyawasam","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","article-title":"NFL is a marker of treatment response in children with SMA treated with nusinersen","volume":"266","author":"Olsson","year":"2019","journal-title":"J. Neurol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Totzeck, A., Stolte, B., Kizina, K., Bolz, S., Schlag, M., Thimm, A., Kleinschnitz, C., and Hagenacker, T. (2019). Neurofilament Heavy Chain and Tau Protein are not elevated in cerebrospinal fluid of adult patients with Spinal Muscular Atrophy during loading with Nusinersen. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215397"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1111\/jcmm.14939","article-title":"Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients","volume":"24","author":"Faravelli","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Bonanno, S., Marcuzzo, S., Malacarne, C., Giagnorio, E., Masson, R., Zanin, R., Arnoldi, M.T., Andreetta, F., Simoncini, O., and Venerando, A. (2020). Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients. Biomedicines, 26.","DOI":"10.3390\/biomedicines8020021"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jnc.14953","article-title":"Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy","volume":"153","author":"Kessler","year":"2020","journal-title":"J. Neurochem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","article-title":"Survival, motor function, and motor milestones: Comparison of AVXS-101 relative to Nusinersen for the treatment of infants with Spinal Muscular Atrophy Type 1","volume":"36","author":"Dabbous","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Connock, M., Andronis, L., Auguste, P., Dussart, C., and Armoiry, X. (2020). Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent \u2018value for money\u2019 for the NHS? A rapid inquiry into suggestions that it may be cost-effective. Expert. Opin. Biol. Ther.","DOI":"10.1080\/14712598.2020.1772747"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone","year":"2019","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_93","unstructured":"ClinicalTrials.gov (2020, May 30). International SMA Patient Registry\u2014Full Text View, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00466349."},{"key":"ref_94","unstructured":"(2020, May 30). TREAT-NMD: National SMA Registries. Available online: http:\/\/www.treat-nmd.eu\/sma\/patient-registries\/sma\/."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","article-title":"SMArtCARE\u2014A platform to collect real-life outcome data of patients with spinal muscular atrophy","volume":"14","author":"Pechmann","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.nmd.2019.08.014","article-title":"Development of an academic disease registry for spinal muscular atrophy","volume":"29","author":"Mercuri","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.nmd.2019.10.001","article-title":"A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy","volume":"29","author":"Messina","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Mercuri, E., Messina, S., Montes, J., Muntoni, F., Sansone, V.A., and All Participants and the SMA PROM Working Group (2020). Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019. Neuromuscul. Disord.","DOI":"10.1016\/j.nmd.2020.02.019"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1590\/1980-57642018dn13-040011","article-title":"Cognitive performance of children with spinal muscular atrophy: A systematic review","volume":"13","author":"Polido","year":"2019","journal-title":"Dement. Neuropsychol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/7\/2222\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:51:00Z","timestamp":1760176260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/7\/2222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":99,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["jcm9072222"],"URL":"https:\/\/doi.org\/10.3390\/jcm9072222","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]}}}